{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"To study the possible mechanisms involved in the clinical antitumor effect with determination of inhibition of angiogenesis","groups":[{"description":"TBL 12, sea cucumber, will be administered orally at a dose of 2 units (20 mL each) twice a day until disease progression","id":"OG000","title":"TBL 12"}],"populationDescription":"immunophenotyping was not performed in this study","reportingStatus":"POSTED","timeFrame":"Antitumor effect","title":"Antitumor Effect","type":"SECONDARY"}